Clinical Trial Finder

Inclusion Criteria:

• - Agree to participate; understand and sign informed consent; - Male and female adults, aged 18 to 50 years, inclusive at Screening; - Generally healthy and medically stable, with no clinically significant abnormalities based on physical examination and laboratory tests as determined by the Investigators; - Have good venous access; - Have normal resting blood pressure and normal heart rate (HR) without history of syncope; a subject with out of range blood pressure may be enrolled in the study at the discretion of the Principal Investigator; - Have a body mass index (BMI) of 18.0 - 30.0 kg/m^2; - Female candidates must be >1 year post-menopausal or practicing a clinically acceptable form of birth control and confirmed by negative urine or serum pregnancy test at Screening; - Negative HIV-Ab, HBs-Ag and HCV-Ab; - Negative alcohol test (urine or breathalyzer); - Negative drug screening results; - Currently non-smoker; have not used any tobacco products for at least three (3) months prior to Screening; and - Demonstrate proficiency in the use of MDI and a consistent inhalation time >2.0 seconds after training, for at least three (3) times, with a maximum of 5 attempts.

Exclusion Criteria:

• - Concurrent clinically significant cardiovascular, hematological, renal, neurologic, hepatic, endocrine, psychiatric, or malignant diseases.

• - Known intolerance or hypersensitivity to any component of the study drugs (i.e., Epinephrine, Albuterol Sulfate or any sympathomimetic drugs, HFA-134a, thymol, ethanol, ascorbic acid, nitric acid, and hydrochloric acid).

• - Upper or lower respiratory tract infection, or other systemic infection within 6 weeks prior to Screening; - Clinically significant abnormalities in the screening/baseline ECG; prolonged corrected QT interval (QTcF) on ECG: men >450ms, women: >470ms; single or multiple premature ventricular contractions (PVC); - Abnormal thyroid function test (if TSH is out of range, refer to T3/T4 for thyroid function assessment); - Subject has been on other investigational drug/device studies within 30 days of Screening Visit or planned participation in another investigational drug trial at any time during this trial; - Women who are pregnant or lactating or planning a pregnancy during the study period; - Subject has donated or lost > 500 mL of blood within 3 months of Screening; - Evidence of alcohol or drug abuse or dependency within 6 months prior to screening; or - Use of any of the prohibited drugs without appropriate washout.

Arms

Interventions